Cargando…
Antiangiogenic therapy using endostatin increases the number of ALDH+ lung cancer stem cells by generating intratumor hypoxia
Antiangiogenic therapy is becoming a promising option for cancer treatment. However, many investigations have recently indicated that these therapies may have limited efficacy, and the cancers in most patients eventually develop resistance to these therapies. There is considerable recently acquired...
Autores principales: | Yu, Yang, Wang, Yu-yi, Wang, Yi-qin, Wang, Xia, Liu, Yan-Yang, Wang, Jian-Tao, Du, Chi, Wang, Li, Li, Mei, Luo, Feng, Jiang, Ming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5050420/ https://www.ncbi.nlm.nih.gov/pubmed/27703219 http://dx.doi.org/10.1038/srep34239 |
Ejemplares similares
-
Antiangiogenic effects of recombinant human endostatin in lung cancers
por: He, Lang, et al.
Publicado: (2018) -
Hypoxia and TGF-β1 lead to endostatin resistance by cooperatively increasing cancer stem cells in A549 transplantation tumors
por: Wang, Yuyi, et al.
Publicado: (2015) -
Comparison of the antiangiogenic activity of modified RGDRGD-endostatin to endostatin delivered by gene transfer in vivo rabbit neovascularization model
por: Ge, Hong-yan, et al.
Publicado: (2011) -
Clinical effects of cisplatin plus recombinant human endostatin (rh-endostatin) intratumoral injection on malignant central airway obstruction: a retrospective analysis of 319 cases
por: Zhou, Yunzhi, et al.
Publicado: (2021) -
Antiangiogenic Polyketides from Peperomia dindygulensis Miq
por: Wang, Qi-Wei, et al.
Publicado: (2012)